Blog

»  Posts By    

Prescription “Red Flags” Pharmacies Should Not Ignore

In the midst of the opioid epidemic, regulators have become increasingly focused on prescriptions that are not issued for a legitimate medical purpose. Pharmacies should be aware of the "red flags" or warning signs that may indicate the presence of a fraudulent or forged prescription, as the DEA and various state Boards of Pharmacy have revoked controlled substances permits and pharmacy licenses for pharmacies that have failed to resolve red...

Frier Levitt Helps Pharmacy Reverse PBM Termination

Frier Levitt recently reversed a PBM's decision to terminate a pharmacy due to alleged drug invoice shortage discrepancies. The pharmacy was terminated due to the results of a PBM's pre-credentialing audit that failed to take into account a variety of purchases made during and prior to the audit period. The PBM also failed to take into account an inventory that was purchased from the previous owner of the pharmacy. Using...

Drug Return Company Ordered to Pay $94 Million in Restitution and $15 Million in Fines for Refund Scheme

Earlier this month, a Pennsylvania federal judge ordered Devos Ltd., a drug return company, to pay over $94 million in restitution and $15 million in fines for failing to channel refunds back to customers and keeping the money for itself. Devos, which does business as Guaranteed Returns, offers middleman services to pharmacies and government agencies who are looking to take advantage of buy-back refunds from drug makers. Instead of issuing...

Pharmacy ALERT: Prime Therapeutics Heightens Investigative Efforts Against Pharmacies with Enhanced Oversight Addendums

Prime Therapeutics is notorious for taking an aggressive stance against its network pharmacies regarding enhanced credentialing criteria.  Over the past year, we have reported numerous instances whereby Prime has sought to terminate pharmacies for alleged credential non-compliance.  In recent weeks, Prime has taken steps to heighten its investigation into pharmacies that have signed Enhanced Oversight Addendums (EOA). These EOAs were offered to pharmacies participating in Prime’s networks in response to...

New DOJ False Claims Act Guidelines: Credit for Disclosure, Cooperation and Remediation

In May, the US Department of Justice (DOJ) issued revised guidelines regarding "taking disclosure, cooperation and remediation into account in False Claims Act (FCA) matters." These guidelines highlight the federal government’s interest in the voluntary disclosure of FCA violations by entities and individuals. The DOJ notes that "entities and individuals that make proactive, timely, and voluntary self-disclosure" to the government may be eligible to receive credit during the resolution of...